Department of Respiratory Medicine, Kowloon Hospital, HKSAR, China.
Harefield Pulmonary Rehabilitation and Muscle Research Laboratory, Royal Brompton and Harefield NHS Foundation Trust, London, UK.
J Cachexia Sarcopenia Muscle. 2019 Dec;10(6):1330-1338. doi: 10.1002/jcsm.12463. Epub 2019 Jun 17.
Cachexia is an important extra-pulmonary manifestation of chronic obstructive pulmonary disease (COPD) presenting as unintentional weight loss and altered body composition. Previous studies have focused on the relative importance of body composition compared with body mass rather than the relative importance of dynamic compared with static measures. We aimed to determine the prevalence of cachexia and pre-cachexia phenotypes in COPD and examine the associations between cachexia and its component features with all-cause mortality.
We enrolled 1755 consecutive outpatients with stable COPD from two London centres between 2012 and 2017, stratified according to European Respiratory Society Task Force defined cachexia [unintentional weight loss >5% and low fat-free mass index (FFMI)], pre-cachexia (weight loss >5% but preserved FFMI), or no cachexia. The primary outcome was all-cause mortality. We calculated hazard ratios (HRs) using Cox proportional hazards regression for cachexia classifications (cachexia, pre-cachexia, and no cachexia) and component features (weight loss and FFMI) and mortality, adjusting for age, sex, body mass index, and disease-specific prognostic markers.
The prevalence of cachexia was 4.6% [95% confidence interval (CI): 3.6-5.6] and pre-cachexia 1.6% (95% CI: 1.0-2.2). Prevalence was similar across sexes but increased with worsening Global Initiative for Chronic Obstructive Pulmonary Disease spirometric stage and Medical Research Council dyspnoea score (all P < 0.001). There were 313 (17.8%) deaths over a median (interquartile range) follow-up duration 1089 (547-1704) days. Both cachexia [HR 1.98 (95% CI: 1.31-2.99), P = 0.002] and pre-cachexia [HR 2.79 (95% CI: 1.48-5.29), P = 0.001] were associated with increased mortality. In multivariable analysis, the unintentional weight loss feature of cachexia was independently associated with mortality [HR 2.16 (95% CI: 1.31-3.08), P < 0.001], whereas low FFMI was not [HR 0.88 (95% CI: 0.64-1.20), P = 0.402]. Sensitivity analyses using body mass index-specific, age-specific, and gender-specific low FFMI values found consistent findings.
Despite the low prevalence of cachexia and pre-cachexia, both confer increased mortality risk in COPD, driven by the unintentional weight loss component. Our data suggest that low FFMI without concurrent weight loss may not confer the poor prognosis as previously reported for this group. Weight loss should be regularly monitored in practice and may represent an important target in COPD management. We propose the incorporation of weight monitoring into national and international COPD guidance.
恶病质是慢性阻塞性肺疾病(COPD)的一种重要的肺外表现,表现为非有意的体重减轻和身体成分改变。既往的研究主要集中在身体成分与体重的相对重要性上,而不是动态与静态测量的相对重要性上。我们旨在确定 COPD 恶病质和前恶病质表型的患病率,并探讨恶病质及其组成特征与全因死亡率之间的关系。
我们纳入了 2012 年至 2017 年间来自伦敦两个中心的 1755 例稳定期 COPD 连续门诊患者,根据欧洲呼吸学会工作组定义的恶病质[非有意体重减轻>5%和低去脂体重指数(FFMI)]、前恶病质(体重减轻>5%但 FFMI 正常)或无恶病质进行分层。主要结局是全因死亡率。我们使用 Cox 比例风险回归计算了恶病质分类(恶病质、前恶病质和无恶病质)和组成特征(体重减轻和 FFMI)与死亡率之间的风险比(HRs),并调整了年龄、性别、体重指数和疾病特异性预后标志物。
恶病质的患病率为 4.6%(95%可信区间:3.6-5.6),前恶病质的患病率为 1.6%(95%可信区间:1.0-2.2)。患病率在性别间相似,但随着全球慢性阻塞性肺疾病呼吸功能障碍分级和改良医学研究委员会呼吸困难评分的恶化而增加(均 P<0.001)。中位(四分位距)随访时间 1089(547-1704)天内有 313 例(17.8%)死亡。恶病质[HR 1.98(95%可信区间:1.31-2.99),P=0.002]和前恶病质[HR 2.79(95%可信区间:1.48-5.29),P=0.001]均与死亡率增加相关。多变量分析显示,恶病质的非有意体重减轻特征与死亡率独立相关[HR 2.16(95%可信区间:1.31-3.08),P<0.001],而低 FFMI 则没有[HR 0.88(95%可信区间:0.64-1.20),P=0.402]。使用体重指数特异性、年龄特异性和性别特异性低 FFMI 值进行的敏感性分析得出了一致的结果。
尽管恶病质和前恶病质的患病率较低,但两者都使 COPD 的死亡率增加,这是由非有意的体重减轻组成部分驱动的。我们的数据表明,没有体重减轻的低 FFMI 可能不会像以前报道的那样导致该组患者的预后不良。在实践中应定期监测体重减轻情况,这可能是 COPD 管理的一个重要目标。我们建议将体重监测纳入国家和国际 COPD 指南。